ILD Malaysia — Galen Centre
Interstitial Lung Disease in Malaysia

Understanding ILD:
Awareness, Research & Care

A resource site on interstitial lung disease in Malaysia.

10,000+
Malaysians affected annually
200+
Distinct ILD subtypes
6.3–71.0
Cases per 100,000
5
Physicians with ILD training
Disease Overview

What is Interstitial Lung Disease?

ILD is an umbrella term for over 200 disorders that cause progressive scarring of lung tissue, impairing breathing and oxygen exchange. Early diagnosis is critical — damage is often irreversible.

Symptoms

Persistent dry cough, shortness of breath during exertion, fatigue, and unexplained weight loss. Early symptoms mimic asthma or COPD, leading to frequent misdiagnosis.

Diagnosis

High-Resolution CT (HRCT) is the gold standard, combined with pulmonary function tests, blood tests, and biopsy. Access to timely HRCT remains uneven across Malaysia.

Causes & Risk Factors

Occupational exposures (silica, asbestos), autoimmune diseases, environmental factors, and certain medications. Many cases, like IPF, have no identifiable cause.

Treatment

Antifibrotic drugs can slow progression; oxygen therapy and pulmonary rehabilitation support quality of life. Severe cases may require lung transplantation.

Local Context

ILD in Malaysia

Despite affecting over 80,000 Malaysians annually, ILD remains under-recognised. Malaysia's multiethnic population and varied geography mean its ILD profile may differ significantly from global data.

1

Late Diagnosis

Symptoms mimic asthma and COPD, meaning ILD is often identified only once fibrosis is irreversible and lung function is already significantly lost.

2

Limited HRCT Access

Scanners are prioritised for cancer staging and infections; specialist radiologist interpretation is uneven outside major hospitals.

3

Specialist Shortage

Only 5 of Malaysia's 41 respiratory physicians have ILD-specific training, creating significant care gaps outside urban centres.

4

No National Registry

The absence of a formal ILD registry limits understanding of local epidemiology, subtypes, and outcomes needed to guide policy and resource allocation.

5

Treatment Costs

Antifibrotic medications and oxygen therapy carry significant out-of-pocket costs, often uncovered by insurance, burdening patients and families.

Publications & Resources

Key publications, papers, and reports on interstitial lung disease in Malaysia.

Policy recommendations

Galen Centre’s foundational report on ILD prevalence, challenges, and policy recommendations for Malaysia published in 2025.

Briefs

Issue briefs on ILD written for policy and decision makers to provide concerns for consideration, recommendations for action, with supporting information relevant to the issue and recommendation.

Event Reports

Summaries from meetings and consultations on ILD organised by the Galen Centre.

Latest ILD Articles

Health journalism on ILD from CodeBlue, the Malaysia’s independent health news platform.

26 December 2025

Include ILD In National Healthy Lung Initiative, Say Experts, Patient, Caregiver
Experts call for ILD inclusion in MOH’s Lung Initiative alongside subsidised antifibrotic medications and oxygen therapy for patients.

8 December 2025

Interstitial Lung Disease: A Serious Respiratory Illness In Malaysia
Respiratory physicians warn of late diagnoses, limited HRCT access, and insufficient specialist training compounding poor ILD outcomes.

17 Ferbruary 2023

An Insight Into The Life Of A Patient With Rare Lung Disease
A patient’s six-month journey to an IPF diagnosis — reflecting the systemic barriers facing ILD patients across Malaysia.

This initiative is supported by Boehringer Ingelheim (Malaysia) Sdn Bhd.